Relmada Therapeutics has closed the depression-era chapter and now trades as a cash-funded bladder-cancer formulation company whose next proof is a manufacturing lot, not another efficacy slide. The second-quarter print did not change the science. It moved the United States investigational filing for NDV-01, the sustained-release gemcitabine and docetaxel gel licensed from Trigone Pharma, from a mid-year target to a year-end target because chemistry, manufacturing, and controls work with contract manufacturer Piramal is still unfinished. That slip is the quarter. The equity is no longer priced as a failed NMDA program. It is priced as an option on whether a ready-to-use office gel can enter two planned Phase 3 pathways before cash discipline has to be tested again.
The tension sits between a striking Israeli Phase 2 durability print and a still-unfiled United States application. Twelve-month complete responses reached seventy-six percent in the evaluable high-risk cohort, with no grade-three treatment-related events and no cystectomies in the disclosed follow-up. Those figures recapitalized the company in March, when a private placement of common stock and pre-funded warrants raised about $150 million of net proceeds. The clearing price on that placement sat just below five a share. Cash, cash equivalents, and short-term investments then stood at $218 million at mid-year. Management states that balance covers operations through the end of the decade, including the planned RESCUE registrational program. Enterprise value after that cash is only a couple of hundred million, which is a modest assignment for two clinical programs and a large assignment for a company that still lacks a cleared United States investigational file.
The second quarter also showed the cost of getting to that file. Research spending more than doubled as study start-up and drug-storage costs replaced last year's license-and-acquisition charges, and operating cash use widened even as general and administrative expense eased. Sepranolone, the Prader-Willi neurosteroid bought from Asarina Pharma, remains a second, smaller clock running toward its own year-end filing. The question the next two quarters resolve is whether Piramal delivers a usable clinical lot in time for both filings, or whether another manufacturing delay forces Relmada to spend the unused Jefferies at-the-market capacity and re-open the dilution debate the March placement was supposed to close.